New Leadership And Pricing Reforms Will Boost Aged Care

Key Takeaways

• New leadership is focused on effective governance and strategic alignment, aiming to enhance earnings and shareholder value through transformation efforts.
  
• Business reorganization and a strong development pipeline are expected to boost operational efficiency, margins, and future revenue growth through increased capacity.
  
• Loss of confidence, financial reporting issues, high debt, and regulatory uncertainties could impact investor trust, profitability, and cash flow in a challenging market.

Catalysts

Develops, owns, and operates integrated retirement villages, rest homes, and hospitals for the elderly people in New Zealand and Australia.

• The new executive leadership team at Ryman Healthcare, including a new CEO with a track record in transformation, aims to rebuild confidence and drive efficient governance and leadership, potentially improving alignment and execution of the company’s strategic objectives, which could enhance earnings.
  
• Ryman is implementing a new pricing structure for retirement village units and aged care services, which, although not immediately impactful on cash, is expected to create significant long-term value for shareholders. This potential for increased revenue per unit is anticipated to have a favorable effect on long-term revenue growth.
  
• The company has embarked on a significant business reorganization to reduce costs and improve operational efficiency, including a focus on centralizing overheads and systems. This effort, resulting in $18 million in annualized savings, is expected to improve net margins over time.
  
• Development of new retirement units and care beds continues at a strong pace, with Ryman delivering 667 units and beds in the first half, and further deliveries expected. This development pipeline supports future revenue growth through increased capacity and occupancy.
  
• Legislative and regulatory changes in the Australian aged care market are deemed positive for Ryman, although the full impact will be realized gradually, potentially enhancing earnings as regulatory conditions stabilize.

Ryman Healthcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Ryman Healthcare's revenue will grow by 8.1% annually over the next 3 years.
• Analysts assume that profit margins will increase from -20.1% today to 62.2% in 3 years time.
• Analysts expect earnings to reach NZ$672.2 million (and earnings per share of NZ$0.66) by about June 2029, up from -NZ$171.3 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 6.2x on those 2029 earnings, up from -13.6x today. This future PE is lower than the current PE for the NZ Healthcare industry at 13.8x.
• Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 10.97%, as per the Simply Wall St company report.

Risks

• Loss of confidence in the Board and management team, alongside issues with financial reporting, could pose a risk to investor trust and potentially impact future earnings and valuations.
  
• A reported net profit before tax loss of $79.8 million and negative cash flow from existing operations might indicate underlying issues with profitability and operational efficiency, affecting net margins.
  
• High levels of debt at $2.56 billion and increased interest costs could strain financial flexibility and impact net earnings due to higher finance expenses.
  
• A challenging property market and slow sales could delay settlements and impact cash flow, influencing revenue recognition timing and liquidity.
  
• Uncertainty regarding regulatory changes and aged care funding in New Zealand and Australia presents potential risks to revenue streams and profit margins if government support does not meet expectations.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of NZ$3.0 for Ryman Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of NZ$3.5, and the most bearish reporting a price target of just NZ$2.56.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NZ$1.1 billion, earnings will come to NZ$672.2 million, and it would be trading on a PE ratio of 6.2x, assuming you use a discount rate of 11.0%.
• Given the current share price of NZ$2.3, the analyst price target of NZ$3.0 is 23.5% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.